denkapparat Operations GmbH Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

denkapparat Operations GmbH bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 12,362 shares of the biopharmaceutical company's stock, valued at approximately $1,142,000. Gilead Sciences makes up about 1.7% of denkapparat Operations GmbH's investment portfolio, making the stock its 7th biggest holding.

Several other institutional investors have also bought and sold shares of GILD. Premier Fund Managers Ltd lifted its holdings in shares of Gilead Sciences by 46.7% in the 4th quarter. Premier Fund Managers Ltd now owns 15,710 shares of the biopharmaceutical company's stock worth $1,445,000 after acquiring an additional 5,000 shares during the last quarter. Orion Portfolio Solutions LLC grew its stake in shares of Gilead Sciences by 3.7% during the fourth quarter. Orion Portfolio Solutions LLC now owns 90,026 shares of the biopharmaceutical company's stock valued at $8,316,000 after buying an additional 3,224 shares during the last quarter. New Age Alpha Advisors LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $10,778,000. Kiltearn Partners LLP lifted its stake in shares of Gilead Sciences by 107.9% during the 4th quarter. Kiltearn Partners LLP now owns 150,900 shares of the biopharmaceutical company's stock worth $13,939,000 after acquiring an additional 78,300 shares during the last quarter. Finally, Norges Bank purchased a new stake in Gilead Sciences in the fourth quarter worth $1,789,254,000. Institutional investors own 83.67% of the company's stock.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,503,250. Company insiders own 0.16% of the company's stock.

Remove Ads

Gilead Sciences Stock Down 0.4 %

Gilead Sciences stock traded down $0.49 during midday trading on Tuesday, reaching $111.56. The company's stock had a trading volume of 2,410,650 shares, compared to its average volume of 7,273,055. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a market cap of $138.93 billion, a P/E ratio of 301.08, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business has a 50-day simple moving average of $105.88 and a 200-day simple moving average of $95.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a $0.79 dividend. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Analysts Set New Price Targets

Several analysts have recently weighed in on GILD shares. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research note on Tuesday, March 11th. Bank of America lifted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group boosted their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.